APA (7th ed.) Citation

JH, W., CR, N., JL, R., MS, S., MJ, M., AL, W., . . . VA, J. (2010). Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. Journal of acquired immune deficiency syndromes (1999), 54(4), 442. https://doi.org/10.1097/QAI.0b013e3181d01d1d

Chicago Style (17th ed.) Citation

JH, Willig, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, Burkhardt JH, Schumacher JE, and Johnson VA. "Cost Ramifications of Increased Reporting of Detectable Plasma HIV-1 RNA Levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Version 1.0 Viral Load Test." Journal of Acquired Immune Deficiency Syndromes (1999) 54, no. 4 (2010): 442. https://doi.org/10.1097/QAI.0b013e3181d01d1d.

MLA (9th ed.) Citation

JH, Willig, et al. "Cost Ramifications of Increased Reporting of Detectable Plasma HIV-1 RNA Levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Version 1.0 Viral Load Test." Journal of Acquired Immune Deficiency Syndromes (1999), vol. 54, no. 4, 2010, p. 442, https://doi.org/10.1097/QAI.0b013e3181d01d1d.